Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Hansa Biopharma AB (publ) is a commercial-stage biopharmaceutical company focused on pioneering the development and commercialization of innovative immunomodulatory treatments for patients with rare immunological conditions. Founded in 2007 and headquartered in Lund, Sweden, the company leverages a proprietary antibody-cleaving enzyme technology platform to target pathogenic IgG antibodies. Its lead product, imlifidase, has received conditional marketing authorization in the European Union as Idefirix for desensitization in highly sensitized adult kidney transplant patients and is advancing toward potential US approval via a Biologic License Application to the FDA. The pipeline includes next-generation enzyme HNSA-5487 and explorations in indications like anti-GBM disease, gene therapy pre-treatments for Duchenne muscular dystrophy with Sarepta Therapeutics, Crigler-Najjar syndrome with Généthon, and others. With 11 clinical and preclinical programs, Hansa Biopharma operates subsidiaries across Europe, the US, and Australia, emphasizing patient-centric innovation, sustainability, diversity, and a workforce representing over 30 nationalities. This positions it as a key player in addressing unmet needs in transplantation, autoimmune diseases, and gene therapy.